Empowering Patients With Self-Administration Drug Delivery Devices

By Bill Welch, Executive Director of Market Development, PCI Pharma Services

Integrating self-administered drug-device combination products into clinical trials benefits both patients and manufacturers. The market for self-administered injectable products is on the cusp of significant therapeutic advancements.

Beyond the usual industry buzzwords, the driving force behind this shift is necessity. This new era for drug-device combinations is addressing future healthcare needs. While it may prove to be revolutionary, it is, above all, a necessary and proactive development.